CLOs on the Move

MY01

www.my01.io

 
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.my01.io
  • 400 Boul de Maisonneuve Ouest Suite 700
    Montréal, QC CAN H3A 1L4
  • Phone: 855.799.6901

Executives

Name Title Contact Details

Similar Companies

Barnett and Ramel Optical

Barnett & Ramel Optical is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Device Innovation Consortium

MDIC is the one place where industry, non-profits, academia & government can collaborate to make patient access to new medical device technologies faster, safer and more cost-effective. MDIC is a public-private partnership facilitating collaboration within the medical device industry. We coordinate the development of methods, tools, and resources used in managing the total product life cycle of a medical device to improve patient access to cutting-edge medical technology.

Cardiocom Multi-Disease Management

Cardiocom Multi-Disease Management is a Chanhassen, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Meinhard Glass Products

Meinhard Glass Products is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ceterix

Ceterix Orthopaedics is singularly focused on meniscal preservation and is dedicated to providing patients every opportunity to maintain the natural health and stability of their knee. The company develops tools that help surgeons repair many of the tears that currently remain untreated or are treated by meniscectomy (meniscus removal), a procedure associated with increased risk of arthritis or total knee replacement later in life. The Ceterix NovoStitch® Plus Meniscal Repair System provides surgeons with the unique ability to repair horizontal, radial, root and other complex tears. Based in Fremont, Calif., the company is backed by investors Novo Ventures, Versant Ventures and 5AM Ventures.